Michele Di Martino

Dr. Michele Di Martino


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MMMichele Di Martino
Michele Di Martino
LPLucia Pacifico
Lucia Pacifico
MBMario Bezzi
Mario Bezzi
RMRossella Di Miscio
Rossella Di Miscio
BSBeatrice Sacconi
Beatrice Sacconi
CCCarlo Catalano
Carlo Catalano
Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents

1 April 2021 in Radiology
Verified
Journal Article
Closed access
SNSilvia Nardelli
Silvia Nardelli
OROliviero Riggio
Oliviero Riggio
LTLaura Turco
Laura Turco
SGStefania Gioia
Stefania Gioia
MPMarta Puzzono
Marta Puzzono
FSFilippo Schepis
Filippo Schepis
Spontaneous portosystemic shunts on CT scans in patients with cirrhosis were associated with higher mortality and risk of complications, including portal vein thrombosis, hepatic encephalopathy, an... Background Cirrhosis leads to portal hypertension and to the consequent formation of spontaneous portosystemic shunts (SPSSs), leading to complications related to the diversion of portal blood into...

Verified
Journal Article
Open access
PDF file
LPLucia Pacifico
Lucia Pacifico
EBEnea Bonci
Enea Bonci
GAGian Marco Andreoli
Gian Marco Andreoli
MMMichele Di Martino
Michele Di Martino
AGAlessia Gallozzi
Alessia Gallozzi
Claudio ChiesaClaudio Chiesa
Claudio Chiesa
The association between nonalcoholic fatty liver disease (NAFLD) and chronic kidney disease has attracted interest and attention over recent years. However, no data are available in children. We determined whether children with NAFLD show signs of renal functional alterations, as determined by estimated glomerular filtration rate (eGFR) and urinary albumin excretion. We studied 596 children with overweight/obesity, 268 with NAFLD (hepatic fat fraction ≥5% on magnetic resonance imaging) and 328 without NAFLD, and 130 healthy normal-weight controls. Decreased GFR was defined as eGFR < 90 mL/min/1.73 m2. Abnormal albuminuria was defined as urinary excretion of ≥30 mg/24 h of albumin. A greater prevalence of eGFR < 90 mL/min/1.73 m2 was observed in patients with NAFLD compared to those without liver involvement and healthy subjects (17.5% vs. 6.7% vs. 0.77%; p < 0.0001). The proportion of children with abnormal albuminuria was also higher in the NAFLD group compared to those without NAFLD, and controls (9.3% vs. 4.0% vs. 0; p < 0.0001). Multivariate logistic regression analysis revealed that NAFLD was associated with decreased eGFR and/or microalbuminuria (odds ratio, 2.54 (confidence interval, 1.16–5.57); p < 0.05) independently of anthropometric and clinical variables. Children with NAFLD are at risk for early renal dysfunction. Recognition of this abnormality in the young may help to prevent the ongoing development of the disease.

26 April 2014 in European Radiology
Verified
Journal Article
Closed access
PDF file
MMMichele Di Martino
Michele Di Martino
LSLuca Saba
Luca Saba
SBSandro Bosco
Sandro Bosco
MRMassimo Rossi
Massimo Rossi
KMKirchin A. Miles
Kirchin A. Miles
CCCarlo Catalano
Carlo Catalano

Verified
Journal Article
Open access
PDF file
DADi Costanzo Alessia
Di Costanzo Alessia
LPLucia Pacifico
Lucia Pacifico
LDLaura D'Erasmo
Laura D'Erasmo
LPLuca Polito
Luca Polito
MMMichele Di Martino
Michele Di Martino
MAMarcello Arca
Marcello Arca
Nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of kidney disease in adults and children. However, it is uncertain whether this association is influenced by major NAFLD susceptibility genes. In a sample of 230 overweight/obese children, 105 with NAFLD (hepatic fat fraction ≥5% by magnetic resonance imaging) and 125 without NAFLD, rs738409 in PNPLA3, rs58542926 in TM6SF2, rs1260326 in GCKR, and rs641738 in MBOAT7 were genotyped. Abnormal kidney function was defined as estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m2 and/or the presence of microalbuminuria (24 h urinary albumin excretion between 30 and 300 mg). In comparison with children without NAFLD, those with NAFLD showed increased prevalence of reduced eGFR (13.3% vs. 1.6%; p < 0.001) and microalbuminuria (8.6% vs. 3.4%, p = 0.025). TM6SF2, GCKR, and MBOAT7 risk alleles did not show any impact on kidney function, while the PNPLA3 G allele was associated with lower eGFR, but only in children with NAFLD (p = 0.003). After adjustment for confounders, NAFLD (OR, 4.7; 95% CI, 1.5–14.8; padj = 0.007), but not the PNPLA3 gene variant, emerged as the main independent predictor of renal dysfunction. Overall, our findings suggest that NAFLD remains the main determinant of decline in kidney function in overweight/obese children, while the PNPLA3 rs738409 prosteatogenic variant has a small impact, if any.

7 November 2023 in Circulation
Verified
Journal Article
Closed access
LDLaura D’eRasmo
Laura D’eRasmo
MMMichele Di Martino
Michele Di Martino
TNThomas Neufeld
Thomas Neufeld
TFTyler J. Fraum
Tyler J. Fraum
CKChul Joo Kang
Chul Joo Kang
NSNathan O. Stitziel
Nathan O. Stitziel
BACKGROUND: ANGPTL3 (angiopoietin-like 3) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of ANGPTL3, reported a dose-dependent increase in hepatic fat. It is unclear whether this adverse effect is due to an on-target effect of inhibiting hepatic ANGPTL3. METHODS: We recruited participants with ANGPTL3 deficiency related to ANGPTL3 loss-of-function (LoF) mutations, along with wild-type (WT) participants from 2 previously characterized cohorts located in Campodimele, Italy, and St. Louis, MO. Magnetic resonance spectroscopy and magnetic resonance proton density fat fraction were performed to measure hepatic fat fraction and the distribution of extrahepatic fat. To estimate the causal relationship between ANGPTL3 and hepatic fat, we generated a genetic instrument of plasma ANGPTL3 levels as a surrogate for hepatic protein synthesis and performed Mendelian randomization analyses with hepatic fat in the UK Biobank study. RESULTS: We recruited participants with complete (n=6) or partial (n=32) ANGPTL3 deficiency related to ANGPTL3 LoF mutations, as well as WT participants (n=92) without LoF mutations. Participants with ANGPTL3 deficiency exhibited significantly lower total cholesterol (complete deficiency, 78.5 mg/dL; partial deficiency, 172 mg/dL; WT, 188 mg/dL; P <0.05 for both deficiency groups compared with WT), along with plasma triglycerides (complete deficiency, 26 mg/dL; partial deficiency, 79 mg/dL; WT, 88 mg/dL; P 0.05 for both deficiency groups compared with WT) or severity of hepatic steatosis as assessed by magnetic resonance imaging. In addition, ANGPTL3 deficiency did not alter the distribution of extrahepatic fat. Results from Mendelian randomization analyses in 36 703 participants from the UK Biobank demonstrated that genetically determined ANGPTL3 plasma protein levels were causally associated with low-density lipoprotein cholesterol ( P =1.7×10 -17 ) and triglycerides ( P =3.2×10 -18 ) but not with hepatic fat ( P =0.22). CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in ANGPTL3 , as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.